Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
January 17, 2005
- Emerging New Therapeutics against Hypercholesterolemia and Atherosclerosis: Lipitor, a Golden Standard?
January 17, 2005
- DIAGNOSTIC NEWS IN BRIEF
January 17, 2005
- Kyorin to Accelerate Drug Discovery by Acquiring ABI
January 17, 2005
- WEBSITE NEWS
January 17, 2005
- Pfizer Strengthens Ties with Customers via Territory Management System
January 17, 2005
- MEDICAL DEVICE NEWS IN BRIEF
January 17, 2005
- BUSINESS NEWS IN BRIEF
January 17, 2005
- New Year's Commentary
January 17, 2005
- WEBSITE NEWS
January 17, 2005
- NEW PRODUCTS
January 17, 2005
- EDITOR'S NOTE
January 3, 2005
- 11 Ingredients/24 Products Including Add. Formulation Products
January 3, 2005
- Special interview
January 3, 2005
- REGULATORY NEWS IN BRIEF
January 3, 2005
- New year's Messages
January 3, 2005
- Chuikyo's Role Should Be Restricted to Price Setting: Council
January 3, 2005
- PhRMA to Actively Discuss Healthcare Reform
January 3, 2005
- NHI Listing of Epzicom, Lexiva Recommended
January 3, 2005
- For Innovation-Friendly and Patient-Oriented Healthcare
January 3, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…